Evidence map›Paper›PMID 36786983›Full record

ArticleDoklady. Biochemistry and biophysics2022

Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation.

T A Gudasheva, K N Koliasnikova, A G Alyaeva, S V Nikolaev, T A Antipova, S B Seredenin

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

T A GudashevaZakusov Research Institute of Pharmacology, Moscow, Russia. tata-sosnovka@mail.ru.
K N KoliasnikovaZakusov Research Institute of Pharmacology, Moscow, Russia.
A G AlyaevaZakusov Research Institute of Pharmacology, Moscow, Russia.
S V NikolaevZakusov Research Institute of Pharmacology, Moscow, Russia.
T A AntipovaZakusov Research Institute of Pharmacology, Moscow, Russia.
S B SeredeninZakusov Research Institute of Pharmacology, Moscow, Russia.
Institute of Pharmacology Russian Academy of Medical Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously, we have shown that the endogenous neuropeptide cycloprolylglycine (CPG) is the positive modulator of AMPA receptors and revealed the dependence of its anxiolytic and antihypoxic action on BDNF/Trk signaling. In the present work, we for the first time conducted in vitro experiments using the AMPA receptor blockers DNQX and GYKI 52466 and the Trk receptor blocker K252a. It is shown that the neuroprotective effect of CPG depends on the activation of both AMPA and Trk receptors.

Indexed as

NeuropeptidesNeuroprotective Agentsalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidBrain-Derived Neurotrophic FactorPeptides, CyclicReceptors, AMPAReceptor, trkBalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidBrain-Derived Neurotrophic Factorcyclo(prolylglycyl)NeuropeptidesNeuroprotective AgentsPeptides, CyclicReceptors, AMPAReceptor, trkBAMPAbrain-derived neurotrophic factor (BDNF)cycloprolylglycineneuroprotective activityTrk

Identifiers

PMID36786983
OpenAlexW4320709544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.